The device used to scale up and manufacture an immunotherapeutic agent is a highly relevant factor in ensuring the most optimal product in terms of the time it takes to produce a dose of the therapy, the risk encountered in processing, the final quality of that product, and the necessary inputs required for production, e.g. cells, reagents, and hands-on time (HoT). In this work, three types of devices for Tcell expansion were compared: a static culture perfusion membrane device (SCPM) device, a rocking bag device (RB), and two sizes of hollow-fiber perfusion bioreactor (HFB-Large and HFB-Small). The Tcell yield, time to dose, fold-expansion (FE) from the initial seed, number of open events (OE), and HoT required for each device were measured. Tcells from three donors were selected from leukopaks and cryopreserved. Upon thaw, Tcells were activated as a pool in a T-flask overnight using a soluble activator. For three donors, 5×106 Tcells were seeded into the HFB-Small and 5×107 Tcells were seeded into the HFB-Large, the RB, and the SCPM. For Donors 2-3, an additional arm seeding 5×107 Tcells into the HFB-Small was also conducted. Both HFB devices and the SCPM were seeded directly, while Tcells for the RB were maintained in T-flasks until the manufacturer's minimum recommended seeding number of 1.5×108 was reached. Tcells were cultured according to each manufacturer's guidance and harvested when the total number of cells was ≥ 2×109, an estimated autologous dose of a Tcell product. Results from each platform were as follows. RB: 2.9×109 Tcells at 98% viability in 8.0 days with 234 min HoT, 6 OE, and a FE of 57.6; SCPM: 2.4×109 Tcells at 98% viability in 9.0 days with 22 min HoT, 4 OE, and a FE of 47.0; HFB-Large: 1.5×1010 Tcells at 98% viability in 4.9 days with 57 min HoT, 1 OE, and a FE of 303.6; HFB-Small bioreactor: 3.0x109 Tcells at 96% viability in 7.8 days with 57 min HoT, 1 OE, and a FE of 613.7. The arms seeding 5×107 Tcells into the HFB-Small yielded an average of 4.9× 109 Tcells at 94% viability in 6.5 days with 1 OE, and a FE of 98.5. When harvested cells were interrogated by flow cytometry, no notable difference was seen between Tcells harvested from all platforms in terms of the expression of TIM-3 and PD-1. The TSCM phenotype (CCR7+/CD45RA+) was displayed in 30% of cells harvested from the RB, 8% of cells from the SCPM, 16% of cells from the HFB-Large, 31% of the cells from the HFB-Small (5M), and 49% of cells from the HFB-Small (50M).